

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

Claims 1-11 (Cancelled).

12 (Currently Amended). A method of inducing the death of undesirable cells ~~and/or stimulating an immune response,~~ comprising administering to a patient in need thereof a) a substance which promotes the targeting of the PML protein towards the nuclear bodies being selected from the group consisting of arsenic trioxide and a caspase inhibitor selected from the group consisting of zVAD and DEVD; and b) the PML protein and/or an agent inducing the overexpression of the PML protein, ~~wherein the death of undesirable cells is not due to apoptosis.~~

Claims 13 and 14 (Cancelled).

15 (Currently Amended). A method of claim ~~[[13]]~~ 12, wherein said caspase inhibitor is zVAD.

16 (Previously presented). The method of claim 12, wherein said agent inducing the overexpression of the PML protein is an interferon.

17 (Previously presented). The method of claim 16, wherein said interferon is selected from the group consisting of  $\alpha$ -interferon,  $\beta$ -interferon and  $\gamma$ -interferon.

18 (Previously presented). The method of claim 12, wherein a) and b) are administered simultaneously or sequentially.

19 (Currently Amended). A method of inducing the death of undesirable cells ~~and/or stimulating an immune response,~~ comprising administering to a patient in need thereof a) an ~~arsenic compound, a compound having the same biological properties as arsenic,~~ arsenic trioxide or a caspase inhibitor selected from the group consisting of zVAD and DEVD ~~or a caspase substrate;~~ and b) an interferon, ~~wherein the death of undesirable cells is not due to apoptosis.~~

Claim 20 (Cancelled).

21 (Currently Amended). A method of inducing the death of undesirable cells *in vitro*, comprising bringing undesirable cells in contact with a) ~~an arsenic compound, a compound having the same biological properties as arsenic,~~ arsenic trioxide or a caspase inhibitor; ~~or a caspase substrate~~ and b) an agent inducing the expression of the PML protein.

Appln. No. 09/744,605  
Amd. dated September 8, 2005  
Reply to Office Action of May 17, 2005

Claims 22 and 23 (Cancelled).

24 (Currently Amended). A method of stimulating an immune reaction, comprising administering to a patient in need thereof a substance chosen from a caspase inhibitor and/or a caspase substrate in combination with an interferon.

25 (Previously presented). The method of claim 24, wherein said caspase inhibitor is zVAD.

26 (New). The method of claim 12, wherein the undesirable cell is a tumor cell.

27 (New). The method of claim 26, wherein the tumor cell is selected from a leukemia or lymphoma cell.

28 (New). The method of claim 12, wherein said caspase inhibitor is DEVD.

29 (New). The method of claim 19, wherein said caspase inhibitor is zVAD.

30 (New). The method of claim 19, wherein said caspase inhibitor is DEVD.

31 (New). The method of claim 21, wherein said caspase inhibitor is zVAD.

Appln. No. 09/744,605  
Amd. dated September 8, 2005  
Reply to Office Action of May 17, 2005

32(New). The method of claim 21, wherein said caspase inhibitor is DEVD.

33(New). The method of claim 24, wherein said caspase inhibitor is DEVD.